Gland Pharma Ltd
Gland Pharma Ltd (GLAND) is scheduled to report results on 3 Nov 2026. Gland Pharma Ltd last reported results for the quarter ended Jun 2026, with sales of ₹1,800 crore and net profit of ₹317 crore. The stock last traded at ₹2,950, a market capitalisation of ₹48,686 crore, on a P/E of 42.5. Over the past 52 weeks the stock has ranged between ₹1,574 and ₹3,042. Figures are as of 6 Oct 2026 and are not real time.
Gland Pharma Ltd share price and key metrics
- Current price
- ₹2,950
- Market cap
- ₹48,686 cr
- Stock P/E
- 42.5
- Book value
- ₹629
- ROE
- 10.7%
- ROCE
- 15.1%
- Dividend yield
- 0.69%
- 52w high / low
- 3042/1574
Metrics as of 6 Oct 2026. Not real time.
Track Gland Pharma Ltd
Cruxal reads every Gland Pharma Ltd filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.
Gland Pharma Ltd growth and returns
- 10 Years
- %
- 5 Years
- 13%
- 3 Years
- 21%
- TTM
- 18%
- 10 Years
- %
- 5 Years
- 1%
- 3 Years
- 8%
- TTM
- 49%
- 10 Years
- %
- 5 Years
- -6%
- 3 Years
- 20%
- 1 Year
- 50%
- 10 Years
- %
- 5 Years
- 11%
- 3 Years
- 9%
- Last Year
- 11%
Gland Pharma Ltd quarterly results
In the quarter ended Jun 2026, sales were ₹1,800 cr, up 19.5% from ₹1,506 cr a year earlier. Net profit was ₹317 cr, up 47.4% year on year.
| ₹ crore | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 1,406 | 1,384 | 1,425 | 1,506 | 1,487 | 1,695 | 1,743 | 1,800 |
| Expenses | 1,109 | 1,024 | 1,077 | 1,138 | 1,173 | 1,260 | 1,230 | 1,311 |
| Operating profit | 297 | 360 | 348 | 368 | 314 | 435 | 513 | 489 |
| OPM % | 21% | 26% | 24% | 24% | 21% | 26% | 29% | 27% |
| Other income | 60 | 58 | 44 | 58 | 84 | 39 | 111 | 61 |
| Interest | 6 | 23 | 7 | 12 | 8 | 4 | 10 | 4 |
| Depreciation | 94 | 96 | 96 | 101 | 106 | 108 | 109 | 111 |
| Profit before tax | 257 | 299 | 288 | 313 | 284 | 362 | 506 | 435 |
| Tax % | 36% | 32% | 35% | 31% | 35% | 28% | 28% | 27% |
| Net profit | 164 | 205 | 187 | 215 | 184 | 261 | 367 | 317 |
| EPS (₹) | 9.93 | 12.42 | 11.32 | 13.08 | 11.15 | 15.87 | 22.26 | 19.21 |
Consolidated figures as reported by the company. Percentages are as published; totals may not sum exactly.
Gland Pharma Ltd annual results
| ₹ crore | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|
| Sales | 2,633 | 3,463 | 4,401 | 3,625 | 5,665 | 5,616 | 6,431 | 6,725 |
| Operating profit | 955 | 1,302 | 1,510 | 1,025 | 1,333 | 1,269 | 1,630 | 1,751 |
| OPM % | 36% | 38% | 34% | 28% | 24% | 23% | 25% | 26% |
| Net profit | 773 | 997 | 1,212 | 781 | 772 | 699 | 1,027 | 1,129 |
| EPS (₹) | 49.88 | 60.94 | 73.75 | 47.42 | 46.90 | 42.40 | 62.35 | 68.49 |
TTM is the trailing twelve months to the most recent quarter.
Gland Pharma Ltd balance sheet
| ₹ crore | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|
| Equity capital | 16 | 16 | 16 | 16 | 16 | 16 | 16 |
| Reserves | 3,631 | 5,887 | 7,141 | 7,942 | 8,707 | 9,134 | 10,341 |
| Borrowings | 5 | 5 | 5 | 4 | 372 | 314 | 284 |
| Other liabilities | 435 | 588 | 671 | 814 | 1,515 | 1,708 | 1,807 |
| Total liabilities | 4,086 | 6,496 | 7,834 | 8,778 | 10,611 | 11,173 | 12,449 |
| Fixed assets | 968 | 954 | 1,502 | 1,571 | 3,947 | 4,147 | 4,492 |
| CWIP | 188 | 338 | 191 | 177 | 238 | 151 | 342 |
| Investments | 0 | 0 | 155 | 0 | 0 | 0 | 0 |
| Other assets | 2,929 | 5,204 | 5,986 | 7,030 | 6,426 | 6,875 | 7,614 |
| Total assets | 4,086 | 6,496 | 7,834 | 8,778 | 10,611 | 11,173 | 12,449 |
As reported by the company. Total assets equal total liabilities by construction.
Gland Pharma Ltd cash flow
| ₹ crore | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|
| Cash from operations | 701 | 605 | 791 | 364 | 997 | 915 | 1,031 |
| Cash from investing | -761 | -1,520 | -999 | 1,211 | -1,749 | 1,718 | 188 |
| Cash from financing | -7 | 1,238 | 35 | 15 | -799 | -433 | -417 |
| Net cash flow | -67 | 323 | -174 | 1,590 | -1,552 | 2,199 | 803 |
| Free cash flow | 530 | 377 | 269 | 141 | 599 | 521 | 538 |
| CFO / operating profit | 99% | 70% | 79% | 66% | 98% | 100% | 91% |
Negative figures are outflows. CFO / operating profit is a ratio, not an amount.
Gland Pharma Ltd operating ratios
| Per year | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|
| ROCE % | — | 28% | 25% | 15% | 14% | 12% | 15% |
| Debtor days | 83 | 71 | 99 | 88 | 100 | 99 | 107 |
| Inventory days | 250 | 312 | 205 | 421 | 278 | 294 | 284 |
| Days payable | 82 | 97 | 80 | 127 | 129 | 143 | 136 |
| Cash conversion cycle | 251 | 286 | 225 | 382 | 250 | 250 | 255 |
| Working capital days | 161 | 169 | 168 | 242 | 155 | 173 | 145 |
Ratios as computed by the source from the reported statements. Rows a company does not report are omitted.
Gland Pharma Ltd shareholding pattern
Promoters held 51.77% at Jun 2026, broadly unchanged since Jun 2025. FIIs 8.74% and DIIs 30.44%.
| % held | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters | 51.83% | 51.83% | 51.83% | 51.83% | 51.83% | 51.83% | 51.83% | 51.77% |
| FIIs | 4.48% | 5.04% | 6.90% | 7.39% | 7.90% | 7.58% | 7.29% | 8.74% |
| DIIs | 35.37% | 34.80% | 33.27% | 32.86% | 32.63% | 32.99% | 33.36% | 30.44% |
| Public | 8.33% | 8.33% | 8.00% | 7.93% | 7.63% | 7.62% | 7.52% | 9.06% |
| No. of shareholders | 1,22,358 | 1,21,075 | 1,13,788 | 1,10,671 | 97,151 | 94,578 | 91,500 | 1,08,266 |
As disclosed by the company to the exchanges. The last row is a count of shareholders, not a percentage.
When is Gland Pharma Ltd’s next results date?
Gland Pharma Ltd’s next results are scheduled for 3 Nov 2026.
- Earnings resultsQ2FY27 earnings release
- Board meetingApproval of appointment of Mr. Xingli Wang as Non-Executive & Non-Independent Director
- Corporate eventAppointment of Mr. Deepak Sapra as the new Chief Executive Officer
See the full results calendar for every Indian company reporting in the next 30 days.
Gland Pharma Ltd corporate filings
- Gland Pharma Ltd publishes newspaper notice for postal ballot dispatchCompany Updatelow impact
Cruxal's analysis: Gland Pharma has issued a notice via newspapers regarding the dispatch of a postal…
Read the full analysis - Gland Pharma Limited seeks shareholder approval for appointment of Mr. Xingli Wang as Non-Executive & Non-Independent Director via postal ballotAGM/EGMmedium impact
Cruxal's analysis: Gland Pharma Limited has announced a postal ballot process to appoint Mr. Xingli Wang…
Read the full analysis - Gland Pharma Approves USD 21 Million Investment in US Subsidiary to Expand US Business, Acquiring 60% Stake in Novelstar Pharma Inc.Othershigh impact
Cruxal's analysis: Gland Pharma Limited has announced a strategic investment of USD 21 million…
Read the full analysis - Fosun Pharma Industrial Pte. Ltd. announces compliance with SEBI regulation for substantial acquisition of shares in Gland Pharma Limited, with total shareholding reaching 51.76% as of September 2026.Insider Trading / SASThigh impact
Cruxal's analysis: Fosun Pharma Industrial Pte. Ltd. has disclosed its substantial acquisition of 51.76%…
Read the full analysis - Closure of Trading WindowInsider Trading / SASTlow impact
- Gland Pharma Limited announces share sale of approximately 4.78 lakh shares at INR 28,942 per share, indicating a significant stake transfer via block dealInsider Trading / SASTmedium impact
Cruxal's analysis: Gland Pharma Limited has executed a share transfer involving approximately 4.78 lakh…
Read the full analysis - Copy of Newspaper PublicationCompany Updatelow impact
- Gland Pharma to streamline corporate structure via internal acquisition of Gland Pharma USA Inc.Otherslow impact
Cruxal's analysis: Gland Pharma Limited has announced the acquisition of 100% equity share capital of its…
Read the full analysis - Gland Pharma allots 44,193 equity shares under ESOP schemeCompany Updatelow impact
Cruxal's analysis: Gland Pharma has announced the allotment of 44,193 equity shares following the exercise…
Read the full analysis - Gland Pharma Ltd grants stock options under Employee Stock Option Scheme 2025Company Updatelow impact
Cruxal's analysis: Gland Pharma has announced the grant of stock options to eligible employees under the…
Read the full analysis - Gland Pharma addresses regulatory fines levied by stock exchangesCompany Updatelow impact
Cruxal's analysis: Gland Pharma has issued a formal board response regarding fines imposed by stock…
Read the full analysis - Gland Pharma Ltd schedules investor meetings for September 2026Company Updatelow impact
Cruxal's analysis: Gland Pharma has issued an intimation regarding scheduled investor meetings. The…
Read the full analysis - Gland Pharma Ltd schedules analyst/investor meetingCompany Updatelow impact
Cruxal's analysis: Gland Pharma has issued an intimation regarding an upcoming analyst/investor meet. The…
Read the full analysis - Fosun Pharma Industrial Pte. Ltd. reduces stake in Gland Pharma Limited by 6.00% via open market saleInsider Trading / SASThigh impact
Cruxal's analysis: Fosun Pharma Industrial Pte. Ltd., a promoter entity of Gland Pharma Limited, has sold 98…
Read the full analysis - Gland Pharma Ltd schedules investor meet for September 2026Company Updatelow impact
Cruxal's analysis: Gland Pharma Ltd has issued an intimation regarding a scheduled analyst/investor meeting…
Read the full analysis - Gland Pharma concludes USFDA inspection at Visakhapatnam facilityCompany Updatelow impact
Cruxal's analysis: Gland Pharma has announced the conclusion of a USFDA inspection at its manufacturing…
Read the full analysis - Gland Pharma Ltd schedules investor meetings for August 31, 2026Company Updatelow impact
Cruxal's analysis: Gland Pharma has issued an intimation regarding a scheduled investor meet. The…
Read the full analysis - Gland Pharma Limited announces successful conclusion of 48th Annual General Meeting and shareholder approval of all resolutionsAGM/EGMlow impact
Cruxal's analysis: Gland Pharma Limited has successfully concluded its 48th Annual General Meeting held on…
Read the full analysis - Gland Pharma Reports Strong FY26 Performance with 47% PAT Growth and Strategic Roadmap Update at 48th AGMAGM/EGMhigh impact
Cruxal's analysis: Gland Pharma Limited held its 48th Annual General Meeting, highlighting a robust FY26…
Read the full analysis - Gland Pharma Ltd schedules investor meet for August 2026Company Updatelow impact
Cruxal's analysis: Gland Pharma Ltd has issued an intimation regarding a scheduled investor meet. The…
Read the full analysis
This page shows filings on a one-hour delay. Sign in to see them as they land, with Cruxal's analysis of what each one means.
Cruxal publishes market data and coverage for information only. Nothing here is investment advice.